Cocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours-Reference-Cited by-同舟云学术

Cocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours

Published:2024 Issue:3 Volume:6 Page:973-984
ISSN:2516-0230
Container-title:Nanoscale Advances
language:en
Short-container-title:Nanoscale Adv.

Author:

Rudolph David¹,Ischyropoulou Myrto²³,Pfeifer Juliana⁴,Napp Joanna²³^ORCID,Schepers Ute⁴^ORCID,Alves Frauke²³⁵^ORCID,Feldmann Claus¹^ORCID

Affiliation:

1. Institute for Inorganic Chemistry (IAC), Karlsruhe Institute of Technology (KIT), Engesserstraße 15, 76131 Karlsruhe, Germany

2. University Medical Center Goettingen (UMG), Institute for Diagnostic and Interventional Radiology, Robert-Koch-Straße 40, 37075 Göttingen, Germany

3. Max-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), Translational Molecular Imaging, Hermann-Rein-Straße 3, 37075, Göttingen, Germany

4. Institute of Functional Interfaces, Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany

5. Clinic of Hematology and Medical Oncology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany

Abstract

ITC/Toc@Gd2(FLP)3 core@shell chemotherapeutic nanocarriers carry a lipophilic irinotecan (ITC) core and a hydrophilic fludarabine phosphate (FLP) shell. Demonstrating potent cytostatic efficacy, especially in pancreatic tumor cells, they hold therapeutic promise across various cancer types.

Funder

Deutsche Forschungsgemeinschaft

Ministerium für Ernährung, Ländlichen Raum und Verbraucherschutz Baden-Württemberg

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Materials Science,General Chemistry,Atomic and Molecular Physics, and Optics,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NA/D3NA00720K

Reference36 articles.

1. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities

2. Nanocarriers as an emerging platform for cancer therapy

3. Doxil® — The first FDA-approved nano-drug: Lessons learned

4. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

5. Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects